DC-targeted vaccination using mAb specific for DEC205, Clec9A and XCR1 induces cytotoxic T cell immunity10–14 that contributes to tumor eradication in prophylactic and therapeutic settings15–17. Here, CLEC9A is linked to neoplasm.